ArticleMediators of inflammation2010
Th1 and Th2 immune response in chronic hepatitis B patients during a long-term treatment with adefovir dipivoxil.
Article in Mediators of inflammation, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 76 citations in OpenAlex.
- Safety, pharmacokinetics, and antiviral efficacy of the novel capsid assembly modulator GST-HG141 in patients with chronic hepatitis B: a phase 1 trial with a randomized, placebo-controlled design.Virology journal · 2024Trial
- Trial
- Antiviral Activity and Pharmacokinetics of the Hepatitis B Virus (HBV) Capsid Assembly Modulator GLS4 in Patients With Chronic HBV Infection.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Trial
- Immunological and antiviral responses after therapeutic DNA immunization in chronic hepatitis B patients efficiently treated by analogues.Molecular therapy : the journal of the American Society of Gene Therapy · 2014Trial
- Interferon therapy-induced reduction in PD-1 + CD8 + and CD160 + CD8 + T cells is associated with functional cure in hepatitis B.BMC infectious diseases · 2025Article
- Pharmacological Evaluation and In-Silico Study of Sabinene as a Potential Anti-Alzheimer's Drug in AlClNeurochemical research · 2025Article
- HBx promotes glomerular podocyte-induced immune cell responses.Renal failure · 2024Article
- Expression of 10 circulating cytokines/chemokines in HBV-related liver disease.Infectious agents and cancer · 2024Article
- The Role of Interleukins in HBV Infection: A Narrative Review.Journal of personalized medicine · 2023Review
- Stat3/IL-6 signaling mediates sustained pneumonia induced by Agiostrongylus cantonensis.PLoS neglected tropical diseases · 2022Article
- Postpartum hepatitis and host immunity in pregnant women with chronic HBV infection.Frontiers in immunology · 2022Review
- Hepatitis B functional cure and immune response.Frontiers in immunology · 2022Review
- Immunopathology of Chronic Hepatitis B Infection: Role of Innate and Adaptive Immune Response in Disease Progression.International journal of molecular sciences · 2021Review
- The balance of type 1 and type 2 immune responses in the contexts of hepatitis B infection and hepatitis D infection.Journal of gastroenterology and hepatology · 2019Article
- Associations of human leukocyte antigen and interleukin-18 gene polymorphisms with viral load in patients with hepatitis B infection.Medicine · 2018Article
- Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients?World journal of gastroenterology · 2018Review
- Decreased frequency of circulating Th9 cells in patients with chronic hepatitis B infection.Journal of clinical laboratory analysis · 2018Article
- Article
- T cell--associated immunoregulation and antiviral effect of oxymatrine in hydrodynamic injection HBV mouse model.Acta pharmaceutica Sinica. B · 2017Article
- Increased frequency of peripheral blood follicular helper T cells and elevated serum IL‑21 levels in patients with knee osteoarthritis.Molecular medicine reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adefovir dipivoxil treatment has significantly improved the outcome of chronic hepatitis B virus (HBV) infection. However, it remains largely unknown how immune system responds to the treatment. Chronic HBV patients were treated with adefovir dipivoxil and examined for serum HBV DNA loads, cytokines, and T helper (Th1) and 2 (Th2) cytokine producing T cells during 104 weeks of the treatment. Th1/Th2 cytokines producing T cells were significantly lower in chronic HBV patients as compared to normal individuals. Adefovir dipivoxil treatment led to the increase of Th1/Th2 cytokines producing T cells and serum cytokine levels in association with the decline of HVB DNA load. In contrast, Th1/Th2 cytokines producing T cells remained lower in one patient detected with adefovir dipivoxil resistant HBV A181T/V mutation. This study has established inverse correlation of the increase of Th1/Th2 immunity and the decline of HBV DNA load in chronic HBV patients during adefovir dipivoxil treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.